Desarae Echevarria1, Alexander Gutfraind2, Basmattee Boodram3, Jennifer Layden4, Jonathan Ozik5, Kimberly Page6, Scott J Cotler1, Marian Major7, Harel Dahari8. 1. The Program for Experimental & Theoretical Modeling, Division of Hepatology, Department of Medicine, Loyola University, Medical Center, Maywood, IL, USA. 2. The Program for Experimental & Theoretical Modeling, Division of Hepatology, Department of Medicine, Loyola University, Medical Center, Maywood, IL, USA; Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, IL, USA. 3. Community Health Sciences, School of Public Health, University of Illinois at Chicago, Chicago, IL, USA. 4. Health Protection Office, Illinois Department of Public Health, Chicago, IL, USA. 5. Consortium for Advanced Science and Engineering, University of Chicago, Chicago, IL, USA; Decision and Infrastructure Sciences, Argonne National Laboratory, Argonne, IL, USA. 6. Division of Epidemiology, Biostatistics and Preventive Medicine, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA. 7. Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. 8. The Program for Experimental & Theoretical Modeling, Division of Hepatology, Department of Medicine, Loyola University, Medical Center, Maywood, IL, USA. Electronic address: hdahari@luc.edu.
Abstract
BACKGROUND AND AIMS: Persons who inject drugs (PWID) are at highest risk for acquiring and transmitting hepatitis C (HCV) infection. The recent availability of oral direct-acting antiviral (DAA) therapy with reported cure rates >90% can prevent HCV transmission, making HCV elimination an attainable goal among PWID. The World Health Organization (WHO) recently proposed a 90% reduction in HCV incidence as a key objective. However, given barriers to the use of DAAs in PWID, including cost, restricted access to DAAs, and risk of reinfection, combination strategies including the availability of effective vaccines are needed to eradicate HCV as a public health threat. This study aims to model the cost and efficacy of a dual modality approach using HCV vaccines combined with DAAs to reduce HCV incidence by 90% and prevalence by 50% in PWID populations. METHODS: We developed a mathematical model that represents the HCV epidemic among PWID and calibrated it to empirical data from metropolitan Chicago, Illinois. Four medical interventions were considered: vaccination of HCV naive PWID, DAA treatment, DAA treatment followed by vaccination, and, a combination of vaccination and DAA treatment. RESULTS: The combination of vaccination and DAAs is the lowest cost-expensive intervention for achieving the WHO target of 90% incidence reduction. The use of DAAs without a vaccine is much less cost-effective with the additional risk of reinfection after treatment. Vaccination of naïve PWID alone, even when scaled-up to all reachable PWID, cannot achieve 90% reduction of incidence in high-prevalence populations due to infections occurring before vaccination. Similarly, the lowest cost-expensive way to halve prevalence in 15 years is through the combination of vaccination and DAAs. CONCLUSIONS: The modeling results underscore the importance of developing an effective HCV vaccine and augmenting DAAs with vaccines in HCV intervention strategies in order to achieve efficient reductions in incidence and prevalence.
BACKGROUND AND AIMS: Persons who inject drugs (PWID) are at highest risk for acquiring and transmitting hepatitis C (HCV) infection. The recent availability of oral direct-acting antiviral (DAA) therapy with reported cure rates >90% can prevent HCV transmission, making HCV elimination an attainable goal among PWID. The World Health Organization (WHO) recently proposed a 90% reduction in HCV incidence as a key objective. However, given barriers to the use of DAAs in PWID, including cost, restricted access to DAAs, and risk of reinfection, combination strategies including the availability of effective vaccines are needed to eradicate HCV as a public health threat. This study aims to model the cost and efficacy of a dual modality approach using HCV vaccines combined with DAAs to reduce HCV incidence by 90% and prevalence by 50% in PWID populations. METHODS: We developed a mathematical model that represents the HCV epidemic among PWID and calibrated it to empirical data from metropolitan Chicago, Illinois. Four medical interventions were considered: vaccination of HCV naive PWID, DAA treatment, DAA treatment followed by vaccination, and, a combination of vaccination and DAA treatment. RESULTS: The combination of vaccination and DAAs is the lowest cost-expensive intervention for achieving the WHO target of 90% incidence reduction. The use of DAAs without a vaccine is much less cost-effective with the additional risk of reinfection after treatment. Vaccination of naïve PWID alone, even when scaled-up to all reachable PWID, cannot achieve 90% reduction of incidence in high-prevalence populations due to infections occurring before vaccination. Similarly, the lowest cost-expensive way to halve prevalence in 15 years is through the combination of vaccination and DAAs. CONCLUSIONS: The modeling results underscore the importance of developing an effective HCV vaccine and augmenting DAAs with vaccines in HCV intervention strategies in order to achieve efficient reductions in incidence and prevalence.
Authors: Jennifer V Campbell; Richard S Garfein; Hanne Thiede; Holly Hagan; Larry J Ouellet; Elizabeth T Golub; Sharon M Hudson; Danielle C Ompad; Cindy Weinbaum Journal: Drug Alcohol Depend Date: 2007-02-02 Impact factor: 4.492
Authors: Lorna E Thorpe; Lawrence J Ouellet; Ronald Hershow; Susan L Bailey; Ian T Williams; John Williamson; Edgar R Monterroso; Richard S Garfein Journal: Am J Epidemiol Date: 2002-04-01 Impact factor: 4.897
Authors: Gregory L Armstrong; Annemarie Wasley; Edgar P Simard; Geraldine M McQuillan; Wendi L Kuhnert; Miriam J Alter Journal: Ann Intern Med Date: 2006-05-16 Impact factor: 25.391
Authors: Murray D Krahn; Ava John-Baptiste; Qilong Yi; Andrea Doria; Robert S Remis; Paul Ritvo; Samuel Friedman Journal: Vaccine Date: 2005-02-18 Impact factor: 3.641
Authors: Yiqing Hu; Lauretta E Grau; Greg Scott; Karen H Seal; Patricia A Marshall; Merrill Singer; Robert Heimer Journal: Am J Prev Med Date: 2008-07 Impact factor: 5.043
Authors: Richard S Garfein; Andrea Swartzendruber; Lawrence J Ouellet; Farzana Kapadia; Sharon M Hudson; Hanne Thiede; Steffanie A Strathdee; Ian T Williams; Susan L Bailey; Holly Hagan; Elizabeth T Golub; Peter Kerndt; Debra L Hanson; Mary H Latka Journal: Drug Alcohol Depend Date: 2007-06-19 Impact factor: 4.492
Authors: Evan Gorstein; Marianne Martinello; Alexander Churkin; Swikriti Dasgupta; Kevin Walsh; Tanya L Applegate; David Yardeni; Ohad Etzion; Susan L Uprichard; Danny Barash; Scott J Cotler; Gail V Matthews; Harel Dahari Journal: Antiviral Res Date: 2020-06-25 Impact factor: 5.970
Authors: Olga V Masalova; Ekaterina I Lesnova; Regina R Klimova; Ekaterina D Momotyuk; Vyacheslav V Kozlov; Alla M Ivanova; Olga V Payushina; Nina N Butorina; Natalia F Zakirova; Alexander N Narovlyansky; Alexander V Pronin; Alexander V Ivanov; Alla A Kushch Journal: Vaccines (Basel) Date: 2020-02-02
Authors: Eric Tatara; Alexander Gutfraind; Nicholson T Collier; Desarae Echevarria; Scott J Cotler; Marian E Major; Jonathan Ozik; Harel Dahari; Basmattee Boodram Journal: PLoS One Date: 2022-03-10 Impact factor: 3.240